Date prepared: 07/25/2023
Abbreviated name of the issuer: CELON PHARMA S.A.
Subject: Receipt of a notification regarding a change in the total number of votes in the Company
Legal basis: Article 70 point 1 of the Act on Public Offering – acquisition or disposal of a significant block of shares
Content of the report:
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that it has received from Generali Powszechne Towarzystwo Emerytalne S.A. a notification dated July 25, 2023 that Generali Otwarty Fundusz Emerytalny (“Generali OFE”) has exceeded the 5% threshold in the total number of votes in Celon Pharma S.A. as a result of the completion of the liquidation of NNLife Otwarty Fundusz Emerytalny (“NNLife OFE”) and the transfer of its assets to Generali OFE.
Following the liquidation of NNLife OFE, Generali OFE holds a total of 4,032,424 shares in the Company, which represents 7.90% of its share capital and entitles it to exercise 4,032,424 votes at its general meeting, i.e. 6.10% of the total number of votes in the Company.
The full text of the notification is attached to this report.